Live news related to CELLECTIS stock (FR0010425595): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The stock of French biotech company Cellectis has risen by 12.06% at mid-session this Monday, November 24, trading at 4.60 euros. This surge is part o…
The value of French biotech Cellectis ended Thursday, November 20th session up by 10.12% at 4.30 euros, driven by the announcement of a major technolo…
Cellectis announces the publication of an article in Nature Communications on the use of single-stranded circular DNA for gene insertion in hematopoie…
Cellectis has reported its third quarter 2025 results, highlighting progress in its clinical programs for lasmé-cel and éti-cel.
Cellectis has announced encouraging results from phase 1 of the BALLI-01 clinical trial for lasmé-cel, targeting patients with relapsed or refractory …
The biotechnology company's stock ended the week at €3.60, up from €2.995 on Monday, marking a 20.2% increase over five trading days. This surge stark…
